The World Health Organization has issued a global alert after Ireland’s health regulator identified multiple batches of substandard contrast agents used in medical imaging procedures. The WHO alert covers ACCUPAQUE, OMNIPAQUE, and VISIPAQUE solutions – essential drugs used in CT scans and other diagnostic procedures worldwide.
Irish Regulator Triggers International Response
The Health Products Regulatory Authority (HPRA) in Ireland first detected the substandard products in March 2026, according to Nigeria’s National Agency for Food and Drugs Administration and Control (NAFDAC). The affected products are presented in 100ml polypropylene containers and distributed across multiple WHO regions.
These contrast agents contain iohexol and iodixanol, compounds critical for enhancing visibility during medical imaging procedures. Substandard versions could compromise diagnostic accuracy or pose direct risks to patients undergoing scans. Healthcare facilities worldwide have been advised to check their inventories immediately.
Multiple Product Lines Affected
The alert encompasses three major contrast agent brands used globally in medical imaging. ACCUPAQUE and OMNIPAQUE both contain iohexol, while VISIPAQUE contains iodixanol – all essential for different types of diagnostic procedures requiring enhanced tissue contrast.
NAFDAC emphasized that healthcare providers should immediately verify the authenticity of these products in their facilities. The agency has strengthened surveillance measures and is coordinating with international partners to prevent distribution of the substandard batches. Additional details about specific quality and safety measures are being developed.
Global Supply Chain Implications
The discovery highlights vulnerabilities in the global pharmaceutical supply chain for critical diagnostic materials. These contrast agents are manufactured by major pharmaceutical companies and distributed worldwide, making quality control lapses particularly concerning for healthcare systems.
The WHO alert system enables rapid communication between national drug regulators when substandard or falsified medical products are identified. This coordinated response helps prevent wider distribution and protects patients across multiple countries and healthcare systems.
Multiple batches of contrast imaging solutions in 100ml polypropylene containers have been identified as substandard, potentially affecting diagnostic procedures worldwide.
— Health Products Regulatory Authority, Ireland (WHO Alert, March 2026)
Key takeaways
- Three major contrast agent brands (ACCUPAQUE, OMNIPAQUE, VISIPAQUE) flagged as substandard globally
- Irish health regulator detection triggered WHO alert across all regions in March 2026
- Healthcare facilities advised to immediately verify product authenticity and strengthen quality controls
Frequently asked questions
What are contrast agents and why are they important?
Contrast agents are specialized solutions injected during medical imaging to enhance visibility of organs and tissues. They are essential for accurate diagnosis in CT scans, MRIs, and other procedures requiring detailed internal imaging.
How can healthcare facilities identify substandard products?
Healthcare providers should verify product authenticity through official supplier channels and check batch numbers against regulatory databases. Any suspicious products should be immediately quarantined and reported to local health authorities.
What risks do substandard contrast agents pose to patients?
Substandard contrast agents may contain incorrect concentrations of active ingredients, impurities, or degraded compounds. This could result in poor image quality, failed diagnoses, or direct adverse reactions in patients receiving the injections.
The WHO alert represents a critical moment for global healthcare quality assurance, demonstrating both the vulnerabilities in pharmaceutical supply chains and the effectiveness of international coordination. Healthcare facilities must now balance immediate patient needs with thorough quality verification, while regulators work to trace and eliminate remaining substandard batches from the global supply network.
